MYC and familial pancreatic carcinoma: Chang et al. identified that oncogenic KRAS upregulated survivin expression by activating extracellular-signal-regulated kinase 1/2 (ERK1/2) in pancreatic cancer cells, which in turn protected MYC from degradation to promote malignant transformation [40].